Multicenter phase II trial of thrice-weekly docetaxel and weekly trastuzumab as preoperative chemotherapy in patients with HER 2-overexpressing breast cancer--Japan East Cancer Center Breast Cancer Consortium (JECBC) 02 Trial

Gan to kagaku ryoho. Cancer & chemotherapy

Volumn 33, Issue 10, 2006, Pages 1411-1415

  Sano, Muneaki ^a   Tabei, Toshio ^a   Suemasu, Kimito ^a   Yanagita, Yasuhiro ^a   Yamamoto, Naohito ^a   Asaga, Taro ^a   Ando, Jiro ^a   Fujii, Hirohumi ^a   Inoue, Kenichi ^a   Sato, Nobuaki ^a   Takei, Hiroyuki ^a   Kurosumi, Masafumi ^a   Honma, Keiichi ^a   Kimura, Morihiko ^a  

^a NIIGATA CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TAXOID; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BIOSYNTHESIS; BREAST TUMOR; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; REMISSION; SEGMENTAL MASTECTOMY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MASTECTOMY, SEGMENTAL; MIDDLE AGED; RECEPTOR, ERBB-2; REMISSION INDUCTION; TAXOIDS;

EID: 33750711726     PISSN: 03850684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)